Kodiak Sciences rises 141.1% after late-stage eye-drug trial meets goals
The company said Zenkuda and tabirafusp-ted met the main goals in wet age-related macular degeneration, with both drugs not inferior to aflibercept at one year.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.